Research on Approaches for Regulation of the “Off-label” use of Medicinal Products in the European Union
Despite the increasingly strict legislation on medicinal products, the „off-label use“ or „use of medicinal product outside the approved summary of product characteristics (SmPC)“ is a weak point of today’s drug regulation and raises many questions about the risk, ethics, and legality of this type o...
Saved in:
Main Authors: | Drenska M., Getov I. |
---|---|
Format: | article |
Language: | EN |
Published: |
Sciendo
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/b42bba9c6cf34f679dee54c7a912cad4 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
by: Han N, et al.
Published: (2021) -
Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study
by: Carla Sans-Pola, et al.
Published: (2021) -
Off-label drugs for weight management
by: Hendricks EJ
Published: (2017) -
Correct Usage of the Term “Off-Label” in the Context of Corneal Cross-Linking [Letter]
by: Katz LJ
Published: (2021) -
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database
by: Lucia Gozzo, et al.
Published: (2021)